title: Effectiveness of long-acting paliperidone palmitate in borderline personality disorder.
abstract: The aim of the present study is to test the efficacy of palmitate paliperidone long-acting injection for patients with borderline personality disorder (BPD). A total of 16 patients with BPD were treated with intramuscular paliperidone palmitate (IMPP) over 12 weeks. Effectiveness measures included the CGI-BPD, HARS, MADRS, BIS-11, and STAXI-2. Functional improvement was assessed using the Global Assessment of Functioning scale. A list of adverse events was provided to clinicians and patients. Treatment with IMPP was associated with a significant average reduction of 1.6 (95% confidence interval: 1192-2008; P>0.01) in CGI-BPD scores and an average increase of psychosocial functioning as scored by the Global Assessment of Functioning scale of 13.3 (95% confidence interval: 8.35-18.31; P>0.01) was obtained. The treatment decreased impulsive-disruptive behaviors and improved general functioning. An acceptable tolerance was observed. The average weight gain was clinically irrelevant despite being statistically significant. No other relevant adverse side effects were reported, with the exception of galactorrhea, which required suspension of treatment in three patients. IMPP seems to be a well-tolerated alternative to other second-generation antipsychotics in the treatment of BPD. More controlled studies replicating these results should be proposed in the future.
authors.affiliation: aInstitute of Health Research of the Hospital Clínico San Carlos (IdISSC) bDepartment of Psychiatry and Medical Psychology, Faculty of Medicine, Universidad Complutense cBiomedical Research Networking Center, Mental Health (CIBERSAM), Hospital Gregorio Marañón, Madrid, Spain.
authors.forename: Nerea
authors.initials: N
authors.lastname: Palomares
authors.forename: Ana
authors.initials: A
authors.lastname: Montes
authors.forename: Marina
authors.initials: M
authors.lastname: Díaz-Marsá
authors.forename: José L
authors.initials: JL
authors.lastname: Carrasco
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001883:Borderline Personality Disorder / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007398:Interpersonal Relations; D008297:Male; D008875:Middle Aged; D000068882:Paliperidone Palmitate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015430:Weight Gain / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D000068882:Paliperidone Palmitate